Business Context and Reporting Period
This Form 8-K Current Report was filed by Kestra Medical Technologies, Ltd. (KMTS) on June 6, 2025, covering events that occurred on June 4, 2025. The Company is incorporated in Bermuda and its common shares trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a current report regarding corporate governance and executive compensation amendments. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Board Election: The Board elected Mr. Conor Hanley as a new independent director, effective immediately. Mr. Hanley brings experience as CEO of Foundry Innovation & Research 1, Ltd. and former senior leadership at ResMed Inc.
- Executive Compensation Amendments: Employment agreements for CEO Brian Webster, CFO Vaseem Mahboob, and General Counsel Traci S. Umberger were amended to redefine "Good Reason" for termination.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The primary operational change involves the definition of "Good Reason" for executive termination, which now includes:
- Material diminution in position, duties, or authorities.
- Demotion below specific executive titles (CEO, CFO, General Counsel).
- Relocation of primary work location outside the Seattle, Washington metropolitan area (applicable to Mr. Webster and Ms. Umberger).
- A 10% or greater reduction in Base Salary or Target Bonus.
- Consummation of a Change in Control.
Mr. Hanley will receive standard compensation for non-employee directors and has not been appointed to any Board committees at this time.
Investor Verification Checklist
- Verify the full text of the amended Employment Agreements for Brian Webster, Vaseem Mahboob, and Traci S. Umberger, which are expected to be filed as exhibits to the Annual Report on Form 10-K.
- Confirm the specific terms of the standard compensatory arrangement for non-employee directors applicable to Mr. Hanley.
- Review the Company's 2025 Omnibus Incentive Plan (Exhibit 10.4 to the March 7, 2025 8-K) for the definition of "Change in Control" referenced in the amendments.